Jianfeng Group Lin2016 -026 (Announcement on Foreign Investment of Subsidists)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-026
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 本公司控股子公司浙江尖峰药业有限公司与德国葛芙制药有限公司、珠海横琴德运嘉国际贸易有限公司签订了《中外合资经营企业合同》,拟在中国浙江省金华市共同出资设立一家中外合资经营企业,致力于建成一个婴幼儿、儿童用药的制药企业。
l 尖峰药业本次拟出资人民币1100万元,占合营公司注册资本的55%。
l 合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
一、对外投资概述
(一)2016年7月12日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)与德国葛芙制药有限公司(以下简称:葛芙制药)、珠海横琴德运嘉国际贸易有限公司(以下简称:德运嘉)签订了《中外合资经营企业合同》,合营各方根据平等互利的原则和长期真诚合作的愿望,努力吸取各自专长和采用适宜的先进技术以及科学的管理方法成立合营公司,并致力于建成一个以婴幼儿、儿童用药制剂研发、生产和销售为主的现代化制药企业。
合营公司中文名称是:浙江金得尔儿婴药品有限公司(以下简称“合营公司”)(以工商行政管理部门核定的名称为准)。合营公司的注册资本为人民币2000万元,其中:尖峰药业以现金人民币1100万元出资,葛芙制药以专有技术的知识产权评估作价人民币500万元出资,德运嘉以现金人民币400万元出资。合营公司拟注册在中国浙江省金华市金西开发区。
(二)本次对外投资,尖峰药业的出资金额为人民币1100万元,根据本公司《章程》有关规定,在董事长对外投资审批权限范围之内,无需提交公司董事会、股东大会审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、协议主题的基本情况
(一)德国葛芙制药有限公司
1、企业名称:德国葛芙制药有限公司(GOHOFF ARZNEIMITTEL GmbH)
2、企业性质:有限责任公司
3、注册地:德国柏林
4、注册日期:2016年3月24日
5、主要办公地点:德国柏林茵塞尔路17号
6、法定代表人:Katharina Bodmeier
7、注册资本:25000欧元
8、主营业务:药品、化学品、化妆品和保健品的开发、销售和贸易
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(欧元) |
出资比例 |
|
1 |
Prof.Dr.Roland Bodmeier |
12500 |
50% |
|
2 |
FangHuang |
11250 |
45% |
|
3 |
Katharina Bodmeier |
1250 |
5% |
(二)珠海横琴德运嘉国际贸易有限公司
1、企业名称:珠海横琴德运嘉国际贸易有限公司
2、企业性质:有限责任公司(自然人独资)
3、注册地:珠海市横琴新区
4、注册日期:2015年06月17日
5、主要办公地点:珠海市横琴新区宝华路6号105室-3754
6、法定代表人:李华智
7、注册资本:500万元人民币,截止公告日实收资本为240万元。
8、主营业务:从事货物与技术的进出口业务;贸易咨询、技术咨询、技术服务;化妆品及卫生用品进出口批发和零售;非许可类医疗器械经营;医疗用品和器材进出口批发和零售;草药和天然产品的进出口批发和零售;保健食品、乳制品进出口批发和零售;动物用健康食品、保健品和药品的进出口批发和零售;药品进出口批发和零售;预包装食品的批发和销售。
9、主要股东:李华智先生占公司注册资本100%。
10、主要财务指标:截止2015年12月31日,德运嘉的资产总额为27.35万元、资产净额5.93万元、营业收入48.54万元、净利润-4.07万元等;
三、合营公司的基本情况
1、企业名称:浙江金得尔儿婴药品有限公司(以工商行政管理部门核定的名称为准)
2、经营范围:保健品和药品进出口,研究、开发、生产和销售婴幼儿用药及其他生物及化学医药产品。
3、注册资本:2000万元人民币
4、出资方式:尖峰药业以现金出资人民币1100万元,占注册资本的55%;葛芙制药以“地西泮栓”、“对乙酰氨基酚栓”两项专有技术评估作价人民币500万元出资,占注册资本的25%;德运嘉以现金出资人民币400万元出资,占注册资本的20%。
5、董事会安排:合营公司董事会由5名董事组成,尖峰药业委派3人,葛芙制药委派1人,德运嘉委派1人。董事长由尖峰药业委派担任,副董事长由葛芙制药委派。董事长、副董事长和董事的任职期限应为四年。
6、管理层安排:合营公司设总经理1名和财务经理1名。总经理由葛芙制药委派,财务经理由尖峰药业委派,任期为四年。
7、无形资产出资情况:葛芙制药以其拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术作价500万元人民币进行出资。金华金辰资产评估有限公司对上述两项专有技术进行评估并出具了《评估报告》,评估价值为555.00万元(大写人民币伍佰伍拾伍万元)。葛芙制药所拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术不存在抵押、质押或者其他重大争议、诉讼或仲裁事项、查封或者冻结等司法措施。
地西泮栓是用于抗焦虑、睡眠障碍,增加肌肉张力的治疗药物;对乙酰氨基酚是用于感冒或感冒引起的发热,也用于缓解轻至中度疼痛。“地西泮栓”、“对乙酰氨基酚栓”都已经在德国上市。中国国家食品药品监督管理总局的网站显示已经有54个“对乙酰氨基酚栓”的批准文号;尚未有“地西泮栓”的批准文号, 但“地西泮”片剂、注射剂已经有较多的批准文号。合资公司成立后将以上述两项专有技术为基础进行相应产品的研发、经营。
四、合同的主要内容
2016年7月12日,尖峰药业(甲方)、葛芙制药(乙方)和德运嘉(丙方)签订了《中外合资经营企业合同》,主要条款有:
1、甲方、乙方和丙方三方将根据《中华人民共和国中外合资经营企业法》、《中华人民共和国中外合资经营企业法实施条例》等其他与本合同相关的法律、法规和规定,按照平等互利的原则,通过友好协商,一致同意在中国浙江省金华市共同设立中外合资经营企业。
2、合营公司注册资本为人民币2000万元。甲方出资额占注册资本的55%,其中以现金出资人民币1100万元。乙方出资额占注册资本的25%,其中以知识产权出资,以评估作价出资人民币500万元。丙方出资额占注册资本的20%,其中以现金出资人民币400万元。
3、以现金出资时,甲、丙双方应于2017年6月30日前缴付认缴的出资;以知识产权出资时,乙方应在公司成立之日起180工作日内,办理知识产权变更登记,将出资用知识产权所有权和使用权转移至合营公司。
4、合营公司租用甲方拥有的位于金华金西开发区尖峰药业制药基地内厂房。甲方同意该场地可用以建成合营公司的药品研发、生产基地。场地租金须不高于市场价,租赁协议另行签订。租赁期限应为中国法律允许的最长期限20年。
5、董事会是合营公司最高权力机构,合营公司的营业执照颁发之日为其董事会成立之日。合营公司的重大事项应由董事会全体一致决定。对于下列事项应由董事会全体董事一致通过方可做出决定:(1)合营企业章程的修改;(2)合营企业的中止、提前终止、解散、清算或延长合营公司期限;(3)合营企业注册资本的增加和减少;(4)合营企业的合并和分立;(5)合营各方向合营公司外的其他方转让股权。
除上述条款外的其它事项应由多数票通过决议决定,但是至少乙方或丙方委派的一名董事投了赞成票。
6、合营公司设总经理1 名和财务经理1 名。总经理应由乙方委派,财务经理应由甲方委派。他们的任期为四年,同样可根据董事会的决定连任。合营公司的其他高层管理人员,由总经理提议,董事会批准后聘请。
7、合营公司的合营期限为30年,从合营公司营业执照签发之日开始。
8、若合资公司决定解散,需进行清算。在制定和执行清算方案的过程中,清算委员会应尽可能将合营公司的产品、产品开发权益、知识产权、专有技术等分配给乙方和/或丙方。
9、除因不可抗力外,若本合同一方在实质性方面不完整、不恰当履行或终止履行本合同,在收到合营其他方通知后六十天内仍不纠正其违约行为时,该方便构成违约,违约方应承担责任,负责赔偿履约方或合营公司由此遭受的损失,赔偿上限不超过认缴的出资额或以非货币财产出资时的非货币财产。
10、本合同的效力,解释,执行,修改,终止及争议的解决,应适用中国法律。已公布的中国法律未涉及事宜,采用国际惯例。
11、在履行本合同及附件过程中发生的一切争议,各方首先应友好协商解决,如争议各方不能协商解决,则经各方书面同意,可将争议提交中国国际经济贸易仲裁委员会按其仲裁程序进行仲裁。仲裁语言采用中文,翻译成英文。仲裁裁决是终局的,并对各方均有约束力。
12、本合同自合营各方签字盖章,并经有权的审批机构批准后生效。
五、对公司的影响
随着我国人口政策的调整,“全面二胎”政策的实施,预计婴幼儿用药市场将迎来快速增长的机遇,本次尖峰药业通过组建合营公司,引进德国技术开发婴幼儿用药,符合公司的发展战略规划,是公司做大做强医药业务的具体实施。
六、可能存在的风险
本次签署的是《中外合资经营企业合同》,合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年七月十二日
More information
On December 30, the group company held a special study meeting. Members of the group's party committee and management team concentrated on learning the spirit of the central economic work conference and the Zhejiang provincial party committee economic work conference. From December 16 to 18, the annual Central Economic Work Conference was held in Beijing, which made it clear that in 2021, "we should continue to implement a proactive fiscal policy and a prudent monetary policy, maintain the necessary support for economic recovery, be more accurate and effective in policy operation, do not make sharp turns, and grasp the effectiveness of the policy. It is necessary to make good use of the precious time window, concentrate on promoting reform and innovation, and take high-quality development as the general tone of the 14th five-year Plan. It is proposed to strengthen the national strategic scientific and technological strength, enhance the independent and controllable ability of the industrial chain supply chain, adhere to the strategic basis of expanding domestic demand, and comprehensively promote reform and opening up. On the 25th, the Zhejiang Provincial Party Committee Economic Work Conference was held in Hangzhou to make specific arrangements for the economic development of Zhejiang Province in 2021. At the study meeting, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, together with the leaders attending the meeting, analyzed and studied the key issues raised at the economic work conference of the central and Zhejiang provincial party committees one by one. In his study and discussion, Jiang Xiaomeng stressed that the current neo-coronary pneumonia epidemic is still spreading around the world, the world economy is in a deep recession, the risk of strong stimulus policies in developed countries has spilled over, the global industrial chain supply chain cycle has been blocked, and international trade and investment have shrunk; major strategic achievements have been made in the prevention and control of the domestic epidemic, and the economy has recovered steadily, but there is still greater uncertainty of instability. China has turned to the stage of high-quality development, the economy has been improving for a long time, the development resilience is strong, and the overall social situation is stable. At the same time, the problem of unbalanced and inadequate development in China is still prominent, the reform task of key links in key areas is still arduous, and the innovation ability is not suitable; at present and in the future, China's development is still in an important period of strategic opportunities, but there are new development and changes in opportunities and challenges, we are accelerating the construction of a new development pattern with the domestic cycle as the main body and the domestic and international double cycle promoting each other. The economic work conference of the Central Committee and the Zhejiang provincial Party committee has set the tone and pointed the way for the future development of enterprises. Party organizations at all levels and enterprise management teams should seriously organize and study, deeply understand the spirit of the conference, correctly understand and judge the future policy direction and industry trend, scientifically plan the work of the new year in combination with the actual work of the enterprise, and promote the better development of the enterprise. (this newspaper reporter)
2021
01-04
A few days ago, Tianjin Jianfeng Flanders Company successfully passed the national high-tech enterprise re-identification review work, and once again joined the ranks of high-tech enterprises after the transformation of the enterprise. The original development orientation of Flanders is pharmaceutical excipients, which belongs to the biomedical industry supported by the state. Its products are mainly aimed at major pharmaceutical factories, with clear product standards and strong technical pertinence, so it has been recognized as a national high-tech enterprise for a long time. Starting from 2019, Flanders has embarked on an industrial transformation in the direction of healthy functional foods. The food industry has a variety of products and serves a wide range of people. Enterprises need to come up with products with unique value in order to be accepted and recognized by the market. The difficulty of identifying high-tech enterprises has also increased accordingly. In order to do a good job in the application evaluation of high-tech enterprises, Flanders, in addition to further combing the achievements of previous technological innovation, has also adjusted and established a high-level R & D team on the basis of establishing postdoctoral workstations in cooperation with Shenyang Pharmaceutical University and Tianjin University of traditional Chinese Medicine, and strengthened technological innovation and intellectual property protection in the direction of new industries. For more than a year, Flanders has successfully transformed, produced and put on the market a number of small molecule functional foods and special dietary products such as Huizhi Gold Drink. In order to further accelerate the pace of development in the health food industry, Flanders has successively joined the Tianjin Health Association, Tianjin Food Safety Association and other food industry organizations; and with the strong support of the Tianjin Association for Science and Technology, it began to prepare for the establishment of the Tianjin Medical and Health Society Health Industry Professional Committee. National high-tech enterprises identified once every three years. The person in charge of Flanders said that the company is currently in a critical period of development and transformation. The identification of high-tech enterprises is not only the recognition of the work of Flanders in the past two years by the competent authorities and the industry, but also will provide assistance to the future development of the company. In the future, Flanders will further increase its scientific research efforts, continue to develop and create new products with high-tech content, and make more contributions to public health. (Liu Hairong)
2020
12-22
On the afternoon of December 2, Sang Weiliang, secretary of the Qiandongnan Prefecture Party Committee of Guizhou Province, Wu Ming, deputy director of the Standing Committee of the State People's Congress, Long Zaichong, deputy secretary-general of the State Party Committee, and the main party and government leaders of Huangping County visited Huangping Jianfeng Cement Co., Ltd. to investigate and investigate, and preach the spirit of the Fifth Plenary Session of the 19th Central Committee of the Party. After visiting and understanding the company's production process, Sang Weiliang said happily: "I am very satisfied with the construction of a modern, clean and standardized cement production line in such a short period of time!" At the peak of Huang Ping, Sang Weiliang conveyed and preached the main contents of the spirit of the Fifth Plenary session of the 19th CPC Central Committee. He pointed out that governments at all levels in Qiandongnan Prefecture should thoroughly study and implement the spirit of the Fifth Plenary session of the 19th CPC Central Committee, earnestly implement the decisions and arrangements of the plenary session, focus on the main line of high-quality development, firmly grasp industrial projects, pay close attention to industrial economy, fully promote high-quality economic and social development, and strive to start a new journey of socialist modernization. We should persist in promoting the "four wheels" of new industrialization, we should pay close attention to the industrial economy, accelerate the transformation and upgrading of industrial industries, improve quality and efficiency, and strive to promote high-quality development and achieve stability and long-term development. During the investigation, Hu Hongwei, general manager of Huang Ping Jianfeng, introduced the basic situation of Jianfeng Group and Huang Ping Jianfeng to the state and county leaders, and focused on the equipment and process advantages of the production line, production process, production process, product quality control indicators, as well as various consumption indicators and emission indicators at the leading level in China. He also reported some problems and difficulties encountered after the formal operation of the enterprise. In view of the deficiencies in road traffic construction in Huangping County, Sang Weiliang asked the transportation department to strengthen communication, report and docking, strive for relevant support, do a solid job in the "14th Five-Year Plan" transportation development plan, further improve the road network connection and improve the transportation system, and provide strong support for the development of advantageous enterprises in Huangping Jianfeng and other regions. Sang Weiliang and his party also conducted in-depth research in the production workshop, checked the operation of the production line, and talked with the line staff. At the end of the investigation, he highly affirmed the construction and production work of Huang Ping Jianfeng for more than a year. The development of enterprises must take the road of sustainable development. It is necessary to ensure product quality and take into account the local ecology in order to develop in a long-term and sustainable manner. Sang Weiliang hopes that the Huangping County Government will do its best to ensure service, firmly establish a sense of service, and actively serve the enterprise. Serve, sincerely solve practical difficulties for the enterprise, create a good business environment, and help the enterprise achieve better development; also hope that Huang Ping Jianfeng will continue to play a pioneering role, jointly promote the high-quality economic and social development of Huangping County. (Pan Yi)
2020
12-22
Beirunning won the "13th Five-Year Chinese Medical Science and Technology Iconic Achievement" Award
From December 8 to 11, under the guidance of China Pharmacists Association, China over the counter drug Association and China Medical Education Association, the "2020 national pharmaceutical economic information conference and rice room annual meeting" sponsored by punctuation information (Group) was held in Guangzhou. During the event, the authoritative professional media of Chinese medicine, "Pharmaceutical Economics", released the list of "13th Five-Year China Pharmaceutical Science and Technology Iconic Achievements" and awarded the honorary certificate. The peak pharmaceutical product Berunning (Olopatadine Hydrochloride Eye Drops) is among them. Great changes have taken place in China's pharmaceutical industry during the 13th Five-Year Plan period. Drug review reform, consistency evaluation, volume procurement and other heavy policies in-depth promotion, driving the pharmaceutical industry innovation and upgrading. Chinese pharmaceutical leading enterprises take advantage of the trend, devote themselves to the development of new drugs, actively promote international registration, expand the international market, carry out international mergers and acquisitions, in the world life science stage blooming Chinese style. Lin Jianning, director of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, combed the current operation of the pharmaceutical economy in detail and led the delegates to think deeply about the new changes in the pharmaceutical market in 2021. The industry authoritative media "Pharmaceutical Economic News" sponsored by the Southern Institute of Pharmaceutical Economics released the "13th Five-Year China Pharmaceutical Science and Technology Iconic Achievements" list during the event. The selection of this award aims to explore the scientific and technological achievements of China's pharmaceutical industry during the 13th five-year Plan period from the dimensions of scientific and technological innovation, clinical efficacy, market share and industry influence, so as to help transform pharmaceutical scientific and technological achievements. to help China move from a big pharmaceutical country to a pharmaceutical power. Pinnacle Pharmaceuticals' product, Berunning, is on the list. Berunning is the first eye drops to pass the consistency evaluation in China, and by virtue of its antagonistic histamine H1-receptor, stable mast cell two-way anti-allergy unique efficacy has been widely concerned. Beirunning in the treatment of children with allergic conjunctivitis has good effect, fast curative effect, will not cause significant mast cell degranulation, so the use of more safe, and almost no adverse reactions to the eye tissue, is the current treatment of allergic conjunctivitis an ideal drug. Since its launch in 2019, Berunning has received unanimous recognition and praise from domestic ophthalmologists. (Xu Yuting)
2020
12-22
On December 15, Xing Zhihong, deputy secretary of the Jinhua Municipal CPC Committee and acting mayor, accompanied by Cai Yan, secretary of the Wucheng District CPC Committee, Huang Guojun, and other leaders, visited the company for research, discussed and exchanged views with the company's management team, and put forward hope for the future development of Jianfeng as a leading enterprise in Jinhua City. Jiang Xiaomeng, chairman of the group company, introduced to Xing Zhihong and his party the development strategy, industrial layout, business performance in recent years, scientific and technological innovation, management innovation, as well as the work in charity, poverty alleviation and so on, which was fully affirmed by Xing Zhihong. Xing Zhihong said in the exchange that the peak is Jinhua's landmark enterprise and Jinhua's pride. It is not easy to stick to the industry for many years. Peak has a clear strategic direction and policy, and its good business performance in recent years has fully proved the courage and foresight of the management team. In view of the current situation that the pattern of economic competition at home and abroad is undergoing tremendous changes and the country's increasing requirements for environmental and ecological development, Xing Zhihong hopes that in the future work, Jianfeng will unswervingly follow the path of innovation and development, further increase investment in innovation and research and development, and further promote Green environmental protection production sets an example for Jinhua enterprises. He also hopes that the peak can "lay out the golden industry in the golden area", not only the enterprise itself through technological innovation to achieve high-quality development, but also further lead the upstream and downstream industries, attract potential and competitive enterprises to invest in Jinhua, forming a cluster effect. The municipal party committee and municipal government will also actively study and introduce better support policies to further optimize the business environment, so that enterprises can do a good job in production and operation without distractions, so that Jinhua can form a better industrial ecology. (this newspaper reporter)
2020
12-22